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Abstract
Background: Historically, traditional Chinese medicine has been widely used to treat stroke. Based on the theory
of Chinese medicine and the modern pharmacological knowledge of herbal medicines, we have designed a
neuroprotective formula called Post-Stroke Rehabilitation (PSR), comprising seven herbs – Astragalus membranaceus
(Fisch.) Bunge, Salvia miltiorrhiza Bunge, Paeonia lactiflora Pall., Cassia obtusifolia L., Ligusticum chuanxiong Hort.,
Angelica sinensis (Oliv.) Diels, and Glycyrrhiza uralensis Fisch. We aim to examine the neuroprotective activity of PSR
in vitro and in vivo, and to explore the underlying molecular mechanisms, to better understand its therapeutic
effect and to further optimize its efficacy.
Methods: PSR extract or vehicle was applied to primary rat neurons to examine their survival effects against N-
methyl-D-aspartate (NMDA)-elicited excitotoxicity. Whole-cell patch-clamp recording was conducted to examine
the NMDA-induced current in the presence of PSR. ERK- and CREB-activation were revealed by western blot
analysis. Furthermore, PSR was tested for CRE promoter activation in neurons transfected with a luciferase reporter.
The protective effect of PSR was then studied in the rat middle cerebral artery occlusion (MCAO) model. MCAO
rats were either treated with PSR extract or vehicle, and their neurobehavioral deficit and cerebral infarct were
evaluated. Statistical differences were analyzed by ANOVA or t-test.
Results: PSR prominently reduced the death of cultured neurons caused by NMDA excitotoxicity in a dose-
dependent manner, indicating its neuroprotective property. Furthermore, PSR significantly reduced NMDA-evoked
current reversibly and activated phosphorylation of ERK and CREB with distinct time courses, with the latter’s
kinetics slower. PSR also triggered CRE-promoter activity as revealed by the increased expression of luciferase
reporter in transfected neurons. PSR effectively reduced cerebral infarct and deficit in neurological behavior in
MCAO rats when PSR decoction was administered starting either 6 days before or 6 h after onset of ischemia.
Conclusions: PSR is neuroprotective both in vitro and in vivo – it protects cultured neurons against NMDA
excitotoxicity, and effectively reduces ischemic injury and neurobehavioral deficit in MCAO rats in both the
pre- and post-treatment regimens. The underlying neuroprotective mechanisms may involve inhibition of NMDA
receptor current and activation of ERK and CREB. This study provides important preclinical data necessary for the
further development of PSR for stroke treatment.
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Background
Stroke, which can be hemorrhagic or ischemic, is caused
by the bursting or blockade of blood vessels, respectively.
It is one of the leading causes of death and disability
worldwide, and 85 % of all stroke cases are ischemic [1–3].
Recombinant tissue plasminogen activator (rtPA), an en-
zyme that breaks down blood clot aiming to restore blood
reperfusion, is the only FDA-approved pharmacological
treatment for ischemic stroke [1–3]. However, its applica-
tion is restricted because of a narrow administration time
window of ~3 to 4.5 h after the initiation of ischemia [4].
Hence, there is an urgent need for novel stroke treat-
ments, and different neuroprotective strategies that coun-
teract the molecular cascades responsible for ischemic
injury have been proposed [3, 5–8]. Mechanisms that con-
tribute to ischemic injury include glutamate excitotoxicity,
oxidative damage, inflammation and apoptosis; molecular
targets for neuroprotection include calcium channel, glu-
tamate receptor, GABAA receptor, PSD95, nitric oxide
synthase and extracellular adhesion molecule [3, 5–8]. In
particular, one neuroprotective strategy targets the N-
methyl-D-aspartate receptor (NMDAR) which plays a
critical role in mediating glutamate excitotoxicity and
neuronal death [9–11]. Interestingly, NMDAR also medi-
ates pro-survival signaling that is beneficial to neuronal
survival upon cerebral ischemic attack, via Akt and ERK
activation [7]. Furthermore, NMDAR-mediated ERK acti-
vation in turn stimulates CREB, a transcriptional factor
which regulates a number of genes critical for long-term
neuroprotective effect [12]. A prevalent view has emerged
to explain the two opposing effects – excitotoxicity and
pro-survival – on neurons upon NMDAR activation: they
are mediated by different NMDAR subtypes containing
GluN2B and GluN2A, respectively [7].
Many neuroprotective compounds have been demon-
strated to be effective in animal models of cerebral is-
chemia, and some candidates are being actively
pursued in clinical trials (e.g. clinical trials with identi-
fiers NCT02315443, NCT02222714, NCT01454154,
NCT01221246, NCT01502761, NCT02144584 and
NCT02535611), including four that mitigate the excito-
toxicity mediated through NMDAR (NCT02315443,
NCT01502761, NCT02144584 and NCT02535611), by
blocking NMDAR channel current or channel inter-
action with PSD95 [6, 8, 11, 13, 14]. It is known that
some traditional Chinese medicine (TCM) preparations
exert neuroprotection with few or no adverse effects,
and some can inhibit NMDAR current [15, 16].
According to traditional Chinese medicine, stroke is
caused by Qi deficiency and blood stasis [17, 18]. For
centuries, various multi-herbal formulas have been used
by Chinese medicine practitioners to treat various dis-
eases [19–21]. Based on the theory of TCM, together
with modern pharmacological knowledge of herbal med-
icines, a neuroprotective formula called Post-Stroke Re-
habilitation (PSR), comprising seven herbs (Table 1) has
been designed. Most chosen herbs have been used in
herbal mixtures for stroke treatment, including Buyang
Huanwu, Sheng Yu, Xiaoxuming, Gualou Guizhi and
Wen Dan Decoctions as well as BNG-1, Hua Tan Tong
Luo formula and Nao-Shuan-Tong [22–30]. Moreover,
extracts and/or isolates from all constituent herbs have
Table 1 Herbal components of PSR and their implications for stroke treatment
Component of PSR Implications for stroke treatmenta
1. Astragalus membranaceus (Fisch.)
Bunge (Huangqi)
A component of Buyang Huanwu Decoctionb (BYHWD), Sheng Yu Decoction and BNG-1 [22, 23, 27]; used
with Honghua to treat stroke patients [17]; its isolates, calycosin and formononetin, were neuroprotective in
cerebral ischemic rats [40, 81]
2. Salvia miltiorrhiza Bunge (Danshen) A component of Hua Tan Tong Luo formula and BNG-1 [27–29]; polysaccharide extract and active isolates,
lithospermic acid, salvianolic acid B, cryptotanshinone, tanshinone I and tanshinones IIA-B, could reduce damages
caused by cerebral ischemia in rodents [41, 82–85]
3. Paeonia lactiflora Pall. (Chishao) A component of BYHWD [22] and Nao-Shuan-Tong [30]; showed proliferative effects on injured rat peripheral
neurons and Schwann cells [31, 32]; an isolate, paeoniflorin, was neuroprotective in cerebral ischemic rats [86]
4. Cassia obtusifolia L. (Juemingzi) Used for hyperlipidemia treatment [44]; showed neuroprotective effects in hippocampal neurons and in cell and
animal models of Parkinson’s disease in mice [33, 34]; an isolate, chrysophanol, showed neuroprotective effect in
ischemic mice [87]
5. Ligusticum chuanxiong Hort.
(Chuanxiong)
A component of BYHW, Sheng Yu, and Xiaoxuming Decoctions [22–24]; butylidenephthalide, ferulic acid and
ligustilide isolated from Chaunxiong were neuroprotective in rodent cells and ischemic rats [36–38, 88]
6. Angelica sinensis (Oliv.) Diels
(Danggui)
A component of BYHWD and Sheng Yu Decoction [22, 23]; ferulic acid and ligustilide isolated from Danggui
showed neuroprotection in rodent cells and ischemic rats [36–38]
7. Glycyrrhiza uralensis Fisch. (Gancao) A component of BNG-1, Xiaoxuming, Gualou Guizhi, and Wen Dan Decoctions [24–27]; used to treat diabetic
acute ischemic stroke [89]; liquiritin, a major constituent, enhanced the neurotrophic effect of NGF [90], showed
protection against Aβ-induced toxicity in rat cortical neurons and ischemic mice [35, 91]
aExamples and references shown are selections highlighted by the authors
bBuyang Huanwu, Sheng Yu, Xiaoxuming, Gualou Guizhi, and Wen Dan Decoctions, BNG-1, Hua Tan Tong Luo formula and Nao-Shuan-Tong are herbal mixtures
that have been used to treat stroke patients in China
Neuroprotection data obtained from in vitro and animal studies are written in italics
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been demonstrated to be neuroprotective in cell and/or
animal models. For examples, extracts from C. obtusifolia
and G. uralensis could protect cultured neurons against
experimental induced-neurotoxicity and P. lactiflora ex-
tract could induce proliferation of injured neurons or
cultured Schwann cells [31–35]; active molecules such as
calycosin isolated from A. membranaceus, tanshinones
from S. miltiorrhiza, chrysophanol from C. obtusifolia,
and ferulic acid and ligustilide from L. chuanxiong and A.
sinensis were neuroprotective in rodent ischemic models
[36–41]. Four of the selected herbal components – A.
membranaceus, P. lactiflora, L. chuanxiong and A. sinensis
– are among the most commonly used herbs for stroke
treatment [42]. In addition to the prominent neuroprotec-
tive properties of S. miltiorrhiza, G. uralensis and C. obtu-
sifolia (Table 1), they were included in PSR because S.
miltiorrhiza, can promote blood circulation and remove
blood stasis [43]; G. uralensis can harmonize the actions
of multiple herbs [43]; C. obtusifolia has been shown to
reduce hyperlipidemia [44, 45], a known risk factor for
stroke [45]. The amount of each herb used in the PSR
mixture is in accordance with the recommendation stated
in the Chinese Pharmacopoeia [43].
To further understand if PSR is an effective treatment
for stroke, preclinical and clinical studies are required. In
this study, we aim to understand the action mechanism of
PSR using in vitro primary embryonic neuron cultures,
which express predominately GluN2B-containing NMDA
receptors [46], and in vivo using the rat middle cerebral
artery occlusion (MCAO) model. Our study indicates
that PSR can protect against NMDA-induced excito-
toxicity, inhibit NMDA-induced current and activate
the pro-survival ERK/CREB signaling in cultured pri-
mary embryonic neurons. Furthermore, PSR is neuro-
protective and attenuates neurological impairments in
MCAO rats when administered either before or after
the onset of ischemia. The present findings offer insights
into the underlying multi-targeted neuroprotective mech-
anism of PSR and provide a scientific basis for its further




Unless otherwise specified, all chemicals, antibodies,
and culture reagents were purchased from Sigma (MO,
USA), Cell Signaling Technology (MA, USA), and Life
Technologies (CA, USA), respectively.
Animals and the MCAO model
Sprague–Dawley (SD) rats were obtained and reared from
the Animal and Plant Care Facility of The Hong Kong
University of Science and Technology. Rats were provided
with food and water ad libitum under a 12/12 h light/dark
cycle. Transient focal cerebral ischemia was induced by
intra-luminal MCAO as described previously [47, 48].
Male SD rats (280–320 g) were anesthetized and placed
on heating pad to maintain rectal temperature at 37 °C. A
nylon filament was advanced from the right external ca-
rotid artery into the lumen of the internal carotid artery to
occlude the right MCA for 2 h, and the filament was sub-
sequently withdrawn to allow reperfusion. The cerebral
blood flow of the rats was monitored closely with Laser
Doppler (PF 5010 – LDPM unit; PERIMED) during the
operation. Sham-treated rats were subjected to the
same operative procedure without the insertion of the
nylon filament. The right femoral artery was cannulated
to monitor arterial blood gases, pH, electrolytes, and
hematocrit. All procedures were approved by the Animal
Ethics Committee of The Hong Kong University of
Science and Technology.
Plant collection and identification
PSR comprises A. membranaceus, S. miltiorrhiza, P. lac-
tiflora, C. obtusifolia, L. chuanxiong, A. sinensis, and G.
uralensis (Table 1). All herbs were purchased from Lee
Hoong Kee Limited, Hong Kong, and collected from dif-
ferent regions of China: A. membranaceus (roots; vou-
cher ID: TCM208-4) and G. uralensis (roots and
rhizomes; TCM080-4) from Inner Mongolia Autono-
mous Region; S. miltiorrhiza (roots and rhizomes;
TCM012-4), P. lactiflora (roots; TCM037-3) and L.
chuanxiong (rhizomes; TCM111-3) from Sichuan; C.
obtusifolia (seeds; TCM238-2) from Anhui; A. sinensis
(roots; TCM800-2) from Gansu. All herbs were authenti-
cated by one of the authors (Dr. Guang-Miao Fu, a
pharmacognosist) and a voucher specimen of each herb
with identification number indicated above was depos-
ited in the herbarium of the Biotechnology Research In-
stitute at the Hong Kong University of Science and
Technology.
PSR preparation and HPLC fingerprinting
The PSR formula was prepared by the National Engineering
Research Center for Modernization of Traditional Chinese
Medicine, Zhuhai, China. The amount of each herb used
in the mixture is in accordance with the recommendation
stated in the Chinese Pharmacopoeia [43]. Briefly, mixture
containing A. membranaceus (15 g), S. miltiorrhiza (10 g),
P. lactiflora (7.5 g), C. obtusifolia (7.5 g), L. chuanxiong
(6 g), A. sinensis (6 g), G. uralensis (6 g) were refluxed with
water (w/v 1:8) for 1 h. The extracts collected were cool-
dried by vacuum into a brown powder. Two batches of
extract were prepared and the yields were ~18 %, respect-
ively. The powder was used for in vitro and in vivo studies.
An HPLC-diode array detection system (Waters) was used
for fingerprint analysis. Each filtered sample (20 μL) was
separated on a C18 column with a mixture of acetonitrile
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and 0.1 % trifluoroacetic acid in water at room
temperature; a gradient elution of acetonitrile from 10–
90 % was applied. Eluents were monitored by the ab-
sorbance at 254 nm.
PSR administration
PSR dissolved in water was orally administered to rats
before and after MCAO. The human-equivalent dose
(HED) in rats was calculated to be 1.1 g/kg. Rats were
dosed with 1.1, 2.2 and 5.5 g/kg and the dosing volume
was 5.5 mL/kg. For the pre-treatment regimen, PSR was
administered daily for 5 days before and 6, 24, and 48 h
after MCAO onset. For the post-treatment regimen, PSR
was administered 6, 24 h, and then daily after MCAO
onset. Deionized water was administered as control.
Evaluation of neurological deficit
Bederson’s neurological examination scoring system [49,
50] was used to evaluate neurological deficit. Rats were
scored 0 if they had no observable deficit (normal); 1 if
they failed to fully extend the left forepaw (mild deficit);
2 if they circled towards the contralateral side (moderate
deficit); and 3 if they lost the ability to walk and righting
reflexes (severe deficit).
Measurement of cerebral infarction and edema extent
After the final evaluation of neurological deficit, rats
were sacrificed and their brains were removed, fixed
with 4 % paraformaldehyde, sectioned into seven 2-mm
coronal slices, and stained with 2 % (w/v) 2,3,5-triphe-
nyltetrazolium chloride (TTC) for 30 min at 37 °C [49].
Images of the slices were taken and analyzed using
ImageJ System software (National Institutes of Health,
Bethesda, MD). The infarct area in each slice was de-
termined by subtracting the TTC-stained area in the
ipsilateral (i.e., ischemic) hemisphere from that of the
contralateral (i.e., non-ischemic) hemisphere and expressed
as the percentage of the TTC-stained area of the contralat-
eral hemisphere. Infarct volume was calculated on the basis
of the infarct area and slice thickness. The ischemia-
induced gain in hemispheric volume (i.e., edema) was cal-
culated by subtracting the volume of the contralateral
hemisphere from that of the ipsilateral hemisphere and
expressed as the percentage of the volume of the contralat-
eral hemisphere.
Primary neuronal cultures
Embryonic cortical and hippocampal neurons express
high levels of GluN2B-containing NMDA receptors and
therefore were used for this study [46]. They were pre-
pared from embryonic day 18 (E18) SD rats as described
previously [51]. Cortical neurons were cultured on
poly-D-lysine–coated plates and maintained in neuroba-
sal medium supplemented with 2 % B-27 supplement,
penicillin (100 units/mL), and streptomycin (100 μg/
mL) at 37 °C in a humidified atmosphere with 5 % CO2.
Hippocampal neurons were grown similarly, except the
medium was supplemented with 0.5 mM L-glutamine.
NMDA excitotoxicity assay and immunohistochemistry
Since a larger quantity of cortical neurons can be obtained
from one embryo compared to hippocampal neurons,
cortical neurons were used for NMDA excitotoxicity
assay. Cortical neurons at 11–12 days in vitro (DIV) were
pre-treated with PSR or vehicle (DMSO) for 2 h and
subsequently rinsed with Locke’s solution (5 mM KCl,
128 mM NaCl, 2.7 mM CaCl2, 1 mM Na2HPO4, 5 mM
HEPES, and 10 mM glucose) followed by a 15-min incu-
bation with glycine-containing (10 μM) Locke’s solution.
The neurons were then co-treated with PSR (or vehicle)
and 20 μM NMDA dissolved in Locke’s plus glycine solu-
tion for 20 min. The neurons were then incubated with
fresh growth medium. After 24 h, NMDA excitotoxicity
was assessed by either the lactate dehydrogenase (LDH)
release assay (Roche) or immunohistochemistry, as de-
scribed previously [52]. The cell death in the presence of
PSR and NMDA was quantified by normalizing the LDH
release to the maximum (vehicle with NMDA, the con-
trol) and minimum (no NMDA) LDH releases. Neurons
were immunostained with β-tubulin type III antibody
(1:1000, Sigma) and labeled with FITC-conjugated sec-
ondary antibody. DAPI (4′, 6-diamidino-2-phenylindole)
was used to stain the nuclei. Images were captured and vi-
sualized by fluorescent microscopy (Leica).
Electrophysiology
Embryonic hippocampal neurons express larger NMDAR
current compared to cortical neurons and were used for
patch clamp recording of the NMDAR current. Whole-
cell recording was performed at room temperature
(~22 °C) as previously described [51, 53]. The pipette solu-
tion contained (in mM): 135 CsCl, 0.5 EGTA, 2 MgCl2, 4
Na2ATP, 0.4 NaGTP, and 10 HEPES (pH 7.25). The bath
solution contained (in mM): 5.3 KCl, 0.4 KH2PO4, 4.2
NaHCO3, 138 NaCl, 0.3 Na2HPO4, and 27.8 glucose, 2.5
CaCl2, 0.01 glycine, 0.0005 tetrodotoxin, 0.02 bicuculline
methiodide (Tocris), and 5 HEPES (pH 7.4). NMDA alone
(20 μM) or with PSR were added to the bath solution.
Pipettes were fire-polished, and resistance was 3–5 MΩ.
Currents were recorded at −70 mV using a Multiclamp
700B amplifier and data were analyzed using pClamp 10
(Molecular Devices, USA).
Western blotting
After treatment, cortical neurons were lysed with RIPA
buffer at different time points. Western blot analysis was
performed as described previously [54]. Briefly, protein
samples (30 μg) were separated by SDS-PAGE and then
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transferred to nitrocellulose membrane, which was sub-
sequently incubated with antibodies specific to phospho-
p44/42 mitogen-activated protein kinase (p-ERK) (1:1000),
p44/42 mitogen-activated protein kinase (ERK) (1:1000),
phospho-cAMP response element-binding protein (p-
CREB) (1:1000), or CREB (1:1000). The membranes were
then washed and incubated with horseradish peroxide-
conjugated secondary antibody (1:2000). Signals were
detected using the SuperSignal West Pico chemilumin-
escent substrate kit (Pierce, Rockford, IL, USA). Band
densitometry was measured and analyzed by ImageJ.
Luciferase reporter assay
Freshly isolated cortical neurons were transiently trans-
fected with the luciferase reporter construct (CRE-Luc)
[55] using Lipofectamine 2000. Transfected neurons
(9–11 DIV) were treated with PSR or vehicle (DMSO)
for 6 h and then lysed with luciferase lysis buffer. Lysates
were transferred onto white-bottom plates and assessed
using a luciferase assay kit (Promega). Luciferase (i.e.,
CRE) activity was quantified using a Promega GloMax™ 96
microplate luminometer.
Statistical analysis
Results are reported as mean ± SEM (or SD if number of
experiments is 2). Data with two dependent variables
(e.g. drug dose and time/coronal slice) were analyzed by
two-way ANOVA followed by Bonferroni post-test; data
with one dependent variable were analyzed by one-way
ANOVA followed by Newman-Keuls post-test, except
when stated otherwise. The level of significance was in-
dicated by *, **, and *** which corresponds to P < 0.05,
<0.01, and <0.0,01, respectively.
Results
HPLC fingerprinting of PSR extracts
To analyze the major chemical components in the
extracts and to assess the quality of extracts obtained from
different batches, samples of PSR were analyzed by HPLC.
A typical chromatogram of a PSR preparation is presented
in Fig. 1. By comparing their retention times and UV spec-
tra to those of the standards, 12 chromatographic peaks
were identified (Table 2). These 12 compounds encompass
the known chemical markers from all the seven herbs
in PSR, and they contribute to the major chemical
composition of the decoction. The quality of the PSR
extracts was routinely monitored and only extracts
containing these 12 peaks in the chromatograms were
used in our experiments.
PSR attenuates NMDA excitotoxicity and reduces NMDA-
induced current in primary cortical neurons
All the signature compounds of PSR, except ononin
(Table 2), have been demonstrated to be neuroprotective
in rodent models of cerebral ischemia, and ononin can
protect neuronal cells against glutamate-induced cytotox-
icity [32, 34, 50–58]. Therefore, it is likely that PSR extract
prepared from our formula can exert neuroprotection.
To investigate whether PSR extract is neuroprotective
in vitro, we employed primary cortical neurons that
have been insulted with NMDA to induce excitotoxi-
city. E18 cortical neurons were treated with PSR extract
for 2 h followed by a 20-min co-incubation with a toxic
dose of NMDA (20 μM). Immunostaining was per-
formed 24 h after NMDA challenge. DAPI and β-
tubulin type III staining were used to indicate nuclei
and neurite networks in neuronal cultures, respectively.
Cortical neurons insulted by NMDA exhibited shrunken
cell bodies with sparse neurites (Fig. 2a). PSR 500 μg/mL
treatment largely restored the intact neurite network in
NMDA-challenged neurons (Fig. 2a). When cell death
was quantified by LDH assay, a dose-dependent pro-
tective effect of PSR on NMDA-treated cells was re-
vealed. PSR 500 to 1000 μg/mL treatment significantly
reduced NMDA-induced cell death in primary cortical
neurons (Fig. 2b). These findings demonstrate that PSR
effectively protects cortical neurons against NMDA-
induced excitotoxicity.
The calcium current induced by NMDA in hippocampal
neurons contributes to its excitotoxicity [56]. To deter-
mine if PSR affects NMDA-evoked current, whole-cell
patch-clamp recording was conducted on hippocampal
neurons. PSR and NMDA co-administration resulted in
reduced current (Fig. 2c). PSR 500 μg/mL significantly
Fig. 1 The HPLC chromatographic fingerprint of PSR. A typical chromatogram contains 12 peaks representing chemical markers of different
component herbs in PSR. The 12 peaks were identified by comparing their retention times and UV spectra with those of the standards (Table 2).
The presence of these 12 compounds indicates that each component herb in PSR contribute to the chemical composition of the extract
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reduced the mean steady state currents by 49 ± 3 %
compared to the control (Fig. 2d). A 5 s wash-out restored
the NMDA-induced current to the control level, indicat-
ing that PSR reversibly inhibits NMDAR current with a
relative fast off-rate.
PSR activates ERK/CREB signaling in primary cortical
neurons
ERK activation has been implicated in protecting neurons
against apoptosis [57, 58]. CREB, a transcription factor
involved in neuroprotection, learning, and memory, is
activated downstream of ERK [59, 60]. To determine
whether PSR can activate ERK and CREB, primary cortical
neurons were treated with PSR 500 μg/mL and the phos-
phorylation levels of ERK and CREB were investigated.
Western blotting revealed that ERK phosphorylation had
already maximally increased after 5 min of treatment and
was maintained at this high level for up to 15 min of treat-
ment, decreasing gradually thereafter to a level still slightly
higher than that of the control (band intensities were
compared at 0 and 180 min of treatment; Fig. 3a, b).
On the other hand, a persistent increase in CREB phos-
phorylation was observed, and at 180 min of treatment,
the increase in CREB phosphorylation was significant.
To verify the activation of CREB, the effect of PSR on
CRE-promoter was examined in primary cortical neurons
transiently expressing a CRE-driven luciferase reporter.
Compared to the control, incubation with PSR 500–
1000 μg/mL significantly activated CRE promoter, as indi-
cated by the increase in luciferase activity (Fig. 3b). Taken
together, these results suggest that PSR may enhance the
survival of neurons by potentiating the pro-survival ERK
and CREB signaling.
PSR pre-treatment reduces functional deficit and ischemic
injury in MCAO rats
Given the in vitro data showing PSR could activate pro-
survival ERK and CREB signaling, inhibit NMDAR
current and counteract NMDA-induced neuronal excito-
toxicity, we explored whether PSR is neuroprotective
against ischemic brain injury using the rat transient
MCAO model (i.e., 2 h occlusion followed by reperfusion)
[50]. We began by examining if PSR could reduce acute is-
chemic injury by using a pre-treatment regimen. MCAO
strongly affected neural behavior as indicated by the
neurological scores of the vehicle control groups mea-
sured at 24, 48 and 72 h after MCAO (score >2; Fig. 4a).
Significant improvements (i.e., decreases) in neurological
scores were observed in rats treated with PSR at all dos-
ages tested at 24 h and the improvements were main-
tained at 48 and 72 h. The cerebral infarct area and
volume were also reduced in PSR-treated rats (Fig. 4b, c
and Additional file 1: Figure S1 in supplemental informa-
tion). The extent of edema was reduced in PSR-treated
rats, although the difference was not statistically signifi-
cant when compared to the control (Fig. 4d). These
data indicate that pre-treating rats with PSR can effect-
ively reduce the functional deficit and cerebral infarct
induced by MCAO. The physiological parameters of
the rats were closely monitored throughout the experi-
ments, and no differences were found after PSR adminis-
tration with respect to mean pH, PaCO2, PaO2, [HCO3
−],
or [Hb] (Additional file 1: Table S1).
PSR post-treatment attenuates functional deficit and is-
chemic injury
In order to investigate the therapeutic efficacy of PSR
against acute stroke in a more clinically relevant set-
ting, PSR was administered 6, 24 and 48 h after MCAO
onset (post-treatment regimen). Rats post-treated with
PSR at all given doses exhibited significant improve-
ments in neurological scores measured 24, 48, and 72 h
after MCAO (Fig. 5a); the greatest improvement was
achieved with PSR 1.1 g/kg. Consistent with the improve-
ment in neural behavior, there were overall reductions in
infarct area and volume in MCAO rats post-treated with
PSR (Fig. 5b, c and Additional file 1: Figure S2). The ex-
tent of edema was reduced in PSR-treated rats, although
not statistically significant (Fig. 5d). As neurological
impairment is a major long-term complication in stroke
patients, we evaluated if PSR can attenuate the devastating
Table 2 Identities and abundances of the 12 marker compounds
corresponding to peaks 1–12 in the chromatogram of PSR shown
in Fig. 1






1 Paeoniflorin 20.20 15.95 ± 0.94 P. lactiflora
2 Ferulic acid 28.57 0.51 ± 0.04 A. sinensis
L. chuanxiong
3 Liquiritin 31.20 0.43 ± 0.05 G. uralensis
4 Ononin 45.78 0.16 ± 0.01 A.
membranaceus
5 Lithospermic acid 48.19 0.64 ± 0.02 S. miltiorrhiza
6 Salvianolic acid B 52.67 1.62 ± 0.04 S. miltiorrhiza
7 Glycyrrhizic acid 68.14 1.41 ± 0.04 G. uralensis
8 Formononetin 68.45 0.53 ± 0.01 A.
membranaceus
9 Ligustilide 75.76 0.25 ± 0.00 A. sinensis
L. chuanxiong
10 Cryptotanshinone 78.78 0.25 ± 0.02 S. miltiorrhiza
11 Tanshinone I 79.39 3.81 ± 0.21 S. miltiorrhiza
12 Chrysophanol 80.18 0.52 ± 0.01 C. obtusifolia
aAll the marker compounds of PSR except ononin have been demonstrated to
be neuroprotective in rodent models of cerebral ischemia, and ononin can
protect neuronal cells against glutamate-induced cytotoxicity [32, 34, 50–58]
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long-term consequences of behavioral impairment in
MCAO rats. In this experiment, rats were post-treated
with PSR 1.1 g/kg for up to 4 weeks and the subsequent
neurological functions were examined once weekly. Com-
pared to the control rats, PSR significantly improved the
neurological scores of rats at 7 and 14 days after
MCAO (Fig. 5e). Taken together, these data demon-
strate that PSR post-treatment can effectively alleviate
ischemic injury and behavioral deficit in rats after cere-
bral ischemia.
Fig. 3 Activation of ERK and CREB by PSR. a Western blots and quantitative densitometry (b) showing the effect of 0–180 min of PSR 500 μg/mL
treatment on ERK and CREB phosphorylation. Band intensities in western blots (n = 2) were quantified using ImageJ. The band intensity of the
phosphorylated ERK/CREB protein is first normalized to that of the corresponding total ERK (or CREB) protein, and then the value of the normalized
band intensity of the phosphorylated protein at time 0 was set as 1. Statistical significance in (b) was performed by one-way ANOVA followed by
Newman-Keuls post-test to compare the band intensity at each time point to that of time 0. c Effect of 6 h-treatment of PSR on the luciferase activity
of neurons transfected with the CRE-Luc construct. Seven concentration-response experiments, with each concentration of PSR conducted in duplicate
wells, were performed. For PSR 100 to 1000 μg/mL, n = 5, 6, 7, 7, 4, respectively. Statistical significance between PSR-treated and control groups was
analyzed by one-way ANOVA followed by Newman-Keuls post-test
Fig. 2 PSR protects neurons against NMDA excitotoxicity. a Rat cortical neurons were treated with vehicle (top panels), 20 μM NMDA (middle
panels), or 20 μM NMDA plus PSR 500 μg/mL (bottom panels). Phase contrast images are shown on the left. The right panels show the overlay of
the DAPI- and β-tubulin III-stained images. b LDH released from NMDA-challenged neurons with or without PSR treatment was measured and
quantified as normalized cell death (see Methods). Four concentration-response experiments, with each concentration of PSR conducted in duplicate
wells, were performed. For PSR 30, 750 and 1000 μg/mL, number of data points (n) = 2; for PSR 100, 300 and 500 μg/mL, n = 4. Statistical significance
between PSR-treated and control groups was analyzed by one-way ANOVA followed by Newman-Keuls post-test. c Representative whole-cell current-
response recorded from a hippocampal neuron. NMDA-induced current was reversibly inhibited by PSR 500 μg/mL. d Inhibitory effect of PSR 500 μg/
mL on NMDA-induced current. The control was the NMDA-induced current level in the absence of PSR (set as 100 %). Statistical significance was
analyzed by paired t-test (n = 4)
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Discussion
PSR is a novel neuroprotective formula designed for
stroke treatment. Its constituent herbs have all been dem-
onstrated with prominent neuroprotective properties. The
further development of PSR for stroke treatment relies on
both preclinical and clinical studies. The work reported
here is a pioneer preclinical study of PSR demonstrating
its neuroprotective efficacy. We first demonstrated that
PSR extract could prominently attenuate cell death using
cultured NMDA challenged-neurons. This in vitro finding
validate the neuroprotective character of the selected
herbal components of PSR. Furthermore, it indicate
that the net activity of all the neuroprotective com-
pounds within the PSR extract persists despite possible
neutralizing interactions that can occur with the many
other molecules presence in the extract. Support by the
in vitro data, PSR was tested in vivo using MCAO rats,
and demonstrated to be effective in reducing cerebral
injury and improving neural behavior. Further in vitro
studies on the effects of PSR on NMDAR currents and
ERK and CREB activation shed insights into its mech-
anism of action.
Our in vivo study demonstrates that PSR pre- and
even post-treatments can effectively decrease ischemic
infarct size and reduce functional neurological impair-
ment in MCAO rats. The effectiveness of pre-treatment
suggests that PSR may be developed for the prophylactic
management of patients with a high risk of stroke recur-
rence [61]. Two aspects of the present post-treatment
data are particularly outstanding. First, PSR acts quickly
to mediate neuroprotection and elicits sustained im-
provement in neurological function in MCAO rats. Im-
provements in neurological scores were observed as
early as 18 h after the first dose of PSR and extended up
to day 14. Second, the therapeutic time window of PSR
in rats is at least 6 h after the onset of MCAO, which is
longer than many other tested compounds/drugs in
similar animal models. As patients with stroke onset
longer than 3 h before therapeutic intervention can be
practically applied is common, the 6 h therapeutic time
window of PSR in MCAO rats increases the chance of
PSR to be successfully translated to human stroke pa-
tients [14, 62].
Our in vitro finding that PSR can reversibly inhibit
NMDA-induced currents with a fast off-rate provides
one possible mechanism underlying the neuroprotec-
tive effect of PSR. A fast off-rate is a desirable pharma-
cological property of an NMDAR current inhibitor
critical for safety [11, 53], and the fast off-rate of PSR is
consistent with the long safety history of the herbal
components of PSR to treat humans. In contrast to
memantine, another NMDAR blocker with fast off-rate
failed to protect against ischemic impairment in rat
when administered 1 h after the onset of MCAO [47],
the superior therapeutic effect of PSR when adminis-
tered 6 h after ischemia suggests that mechanisms
other than NMDAR current inhibition is involved in
mediating its potent neuroprotective effect.
Increasing evidence shows that single-targeted drug
candidates are ineffective for stroke treatment [63]. As
TCM formulas contain multiple herbs designed and as-
sumed to act synergistically [19–21], their pharmaco-
logical actions are usually multi-targeted. PSR indeed has
multiple targets – in addition to inhibiting NMDAR-
mediated current, PSR can activate ERK and CREB, which
Fig. 4 PSR pre-treatment reduces neurological deficit and cerebral
infarct in MCAO rats. a Rats were pre-treated with vehicle (con) or
different doses of PSR, and neurological scores were determined 24,
48, and 72 h after MCAO. Infarct area (b), infarct volume (c), and
edema content (d) were measured 72 h after MCAO. For (a-c), the
numbers of animals in the control, PSR 1.1, 2.2 and 5.5 g/kg groups
were 17, 7, 10 and 10, respectively. For (D), n for control = 14. In
(a, b), statistical significance between PSR-treated and control groups
was analyzed by two-way ANOVA followed by Bonferroni post-test. For
infarct area, the P-values of the differences between treatment groups
and the corresponding controls of the same coronal slices are shown.
In (c, d), statistical significance between PSR-treated and control
groups was analyzed by one-way ANOVA followed by Newman-
Keuls post-test. The key pattern shown in (a) applies to all other
panels in this figure as well as in Fig. 5
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may potentiate the expression of CREB-mediated genes
such as growth factors and anti-apoptotic proteins to exert
neuroprotective effects [64–67]. Two of the constituent
herbs, A. sinensis and L. chuanxiong, have been demon-
strated or implicated in activating CREB – pretreatment
of cortical neuron culture with extract of A. sinensis pre-
vented the reduction of phospho-CREB induced by amyl-
oid beta peptide, and extract of L. chuanxiong induced
CREB phosphorylation in PC12 cells [68, 69]. However, to
the best of our knowledge, no decoction has been re-
ported to enhance ERK and CREB signaling in cultured
primary neurons. Only until recently, a decoction of thir-
teen herbs to treat memory impairment of schizophrenia
patient was shown to activate ERK and CREB in hippo-
campi of treated animals [70]. Moreover, PSR likely acts
on other targets in addition to NMDAR and ERK/CREB,
as all its seven constituent herbs except C. obtusifolia have
been implicated to have both anti-oxidative and anti-
inflammatory effects, while C. obtusifolia has been impli-
cated to have only anti-inflammatory effect [71–77]. In
future experiments, it will be important to demonstrate
the anti-oxidative and anti-inflammatory effects of PSR
extract, and explore other plausible mechanisms that can
contribute to its neuroprotective effect.
There are two possible directions regarding the further
development of PSR. First, the PSR extract, although a
complex molecular mixture, can be further investigated
and developed for stroke treatment. Such effort requires
the preparation of a quality-controlled extract from the
seven constituent herbs, which in turn relies on stan-
dardized good practice to ensure the use of high quality
herbs, a consistent procedure for extract preparation
and chemical profiling to validate the quality the extract
[78, 79]. Alternatively, the extract can be simplified by
systematically purifying molecular fractions from the
seven herbs, identifying the active molecules, and mixing
the active molecules in optimized molar ratio to gener-
ate a cocktail which can achieve the best neuroprotective
effects. The optimized molar ratio of the active mole-
cules can be derived by using computational algorithm
coupled to bioassays [80].
Conclusions
Extract of PSR, a novel Chinese herbal formula, is neuro-
protective in cultured neurons and is effective in reducing
ischemic injury in MCAO rats in both the pre- and post-
treatment regimens, and the underlying neuroprotective
mechanisms may involve inhibition of NMDA receptor
Fig. 5 PSR post-treatment reduces neurological deficit and cerebral infarct in MCAO rats. a Rats were post-treated with vehicle (con) or different
doses of PSR, and neurological scores were determined 24, 48, and 72 h after MCAO. Infarct area (b), infarct volume (c), edema content (d) were
measured 72 h after MCAO. e Adult rats were post-treated with vehicle (con) or PSR 1.1 g/kg for up to 28 d after MCAO. Neurological scores measured
at 7, 14, 21, and 28 d after MCAO are shown. For (a-c), the numbers of animals in the control, PSR 1.1, 2.2 and 5.5 g/kg groups were 17, 9, 12 and 9,
respectively. For (d), n for control = 13. For (e), the numbers of animals for control and PSR 1.1 g/kg groups at day 7, 14, 21 and 28 were 17, 17, 9, 8
and 16, 14, 9, 8, respectively. In (a, b) and (e), statistical significance between PSR-treated and control groups was analyzed by two-way ANOVA
followed by Bonferroni post-test, respectively. In (c-d), statistical significance between PSR-treated and control groups was analyzed by one-way
ANOVA followed by Newman-Keuls post-test
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current and activation of ERK and CREB. As neuroprotec-
tion strategies continue to show promise in the treatment
of ischemic and hemorrhagic types of strokes, our study
provides the scientific basis and critical preclinical data for
further development of PSR for stroke treatment.
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